To assess whether these findings in mouse models might correspond to patterns of resistance to anti-PD-1 therapy in lung cancer patients, we analysed samples from two lung cancer patients who were treated with anti-PD-1 antibodies and five samples from lung cancer patients who were not treated with immune modulating agents. This evidence concerns the gene PDCD1 and lung carcinoma.